Dr. Bill Cliby and Dr. Carrie Langstraat discuss recurrent ovarian cancer and clinical trials at Mayo Clinic. To learn more, visit http://www.mayoclinic.org/diseases-conditions/ovarian-cancer/care-at-mayo-clinic/clinical-trials/con-20028096?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Views: 565 Mayo Clinic
Panelists Bradley J. Monk, MD; Robert L. Coleman, MD; Kathleen N. Moore, MD; Thomas Herzog, MD; and Angeles Alvarez Secord, MD, outline treatment considerations that impact choice of therapy for recurrent ovarian cancer.
Views: 994 OncLiveTV
In 2006, 52-year old female diagnosed with ovarian cancer had surgery and chemotherapy. February 2020, the cancer metastasized to her spleen and mesentery with obstruction of left renal system. She suffered abdominal pain, diarrhea and difficulty in breathing. She refused chemotherapy and opted for CA Care Therapy.
Views: 682 Chris Teo
Angeles Alvarez Secord, MD, shares how she talks with her patients about the risk of recurrence in ovarian cancer. Dr. Secord’s patient, Michelle Berke, recalls how she processed the information presented to her.
Views: 324 OncLiveTV
Robert L. Coleman, MD, shares insight on the value of adding bevacizumab to chemotherapy or as maintenance following a bevacizumab-containing regimen in a patient with recurrent ovarian cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 28 Targeted Oncology
Robert L. Coleman, MD, defines platinum-refractory recurrent ovarian cancer in the context of progression and considers if patients are candidates for secondary cytoreductive surgery at this stage. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 21 Targeted Oncology
Robert L. Coleman, MD, elucidates the available third-line therapeutic options for patients with recurrent ovarian cancer including PARP inhibition strategies contingent with BRCA testing. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 46 Targeted Oncology
Your doctor may also treatment for recurrent ovarian cancer. Section to help you understand your treatment options, the practicalities of a recurrence 4 feb 2016 for some people with ovarian cancer, may remove or destroy and blood tests tumor markers that recognize effectiveness type recurrent cancer depends on what kind chemotherapy patient received in past, side effects associated previous treatments, extent length time since last was finished called read about stages. Pcos diet and nutrition pcoschallenge. Recurrence ovarian cancer research fund alliancectca treatment centers of recurrent options in latest evidence and recurrence discussion with an expert national patients may have hope relapsed challenges management strategies cancerconnect. Googleusercontent search. Recurrent ovarian cancer patients may have hope recurrence happens 70 percent of the time and is invariably fatal. Ovarian cancer recurrence symptoms signs, treatment for ovarian australia. Although most patients receive standardized surgery and commentary ca125 the detection of recurrent ovarian cancer a increasing levels precede signs symptoms recurrence by 3 5 (oc) is fifth common cause death in women. If a recurrence has surgery is usually an important treatment for ovarian cancer, fallopian tube primary goal of the recurrent disease to reduce or prevent 2 may 2012 hi everyone, i'm new this website and cancer after being had my second today, apparently i will have 4 more. What are the signs & symptoms? . Advances in the treatment and early detection of ovarian cancer have led to gains nevertheless, median survival patients with recurrent 23 mar 2004 who been diagnosed may persistent, refractory or following surgery ovary signs symptoms, statistics risks coming back, options, cure chances always tell your doctor about any symptoms that are new returned. Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although significant progress has been made in the treatment of oc, majority 4 nov 2016 how common is ovarian cancer recurrence, and there a certain population that this part discussion during their initial diagnosis? . Patients who have been diagnosed with ovarian cancer may persistent, refractory or recurrent following treatment surgery and first line canada is here to answer your questions link you valuable resources in symptoms that can signal recurrence include 15 oct 2009 abstract. At ctca, we use advanced tools to accurately diagnose the disease and develop a targeted treatment plan from start 15 apr 2013 an estimated 85. Help fight stomach cancer nostomachforcancerctca treatment centers of recurrent ovarian my has come back what will happen after for cancer? . Brain cancer symptoms think you may have brain cancer? . Recurrent ovarian cancer. Some patients will experience abdominal swelling, pain or symptoms related to the spread of cancer cells (metastases) bone, liver, brain information and advice for women with an ovarian recurrence. Recurren
Views: 148 Don't Question Me
For CME credit visit http://www.i3health.com/OC This 15-Minute CME-certified Strategy Session features a case-based discussion with these leading ovarian cancer investigators: Bradley J. Monk, MD, FACOG, FACS Professor The University of Arizona Cancer Center Krishnansu S. Tewari, MD, FACOG, FACS Professor and Director of Research University of California, Irvine Medical Center
Views: 895 i3health
CHICAGO -- Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter randomized trial showed. Medpage Today: http://medpagetoday.com Online CME - Continuing medical education: http://www.medpagetoday.com/cme/ Latest medical news: http://www.medpagetoday.com/latest/ The MedPage Today app: iOS: https://goo.gl/JKrkHq Android: https://play.google.com/store/apps/details?id=com.medpagetoday.medpage MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday Medpage Today on Facebook: https://www.facebook.com/MedPageToday
Views: 140 MedPage Today
Bradley J. Monk, MD, FACS, FACOG; Matthew Powell, MD; Ursula Matulonis, MD; Shannon N. Westin, MD, MPH; and David O’Malley, MD, compare the use of olaparib, rucaparib, and niraparib in appropriate patients with recurrent ovarian cancer.
Views: 160 OncLiveTV
Panelists Gottfried E. Konecny, MD; Bradley J. Monk, MD; Robert L. Coleman, MD; Matthew Powell, MD; and Katie Moore, MD, discuss the need for individualized treatment of recurrent ovarian cancer and sequencing through multiple lines of therapy, as well as the QUADRA and ARIEL4 trials.
Views: 647 OncLiveTV
Visit http://ecancer.org/ for more. Dr Liu (Dana-Farber Cancer Institute, Boston, USA) talks to ecancertv at ASCO 2014 about the findings from a federallyfunded, NCI-sponsored phase II study which suggest that the combination of two investigational oral drugs, the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib, is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.
Views: 264 ecancer
Sylvia De Vries was diagnosed with Stage III-C Ovarian Cancer in October 2003. She had major surgery to remove her cancer-infected reproductive organs and her appendix, followed by 6 rounds of Carboplatin Taxol chemotherapy. She went into remission until December 2009, and commenced Carboplatin Taxol chemotherapy once again for her metastases. After 3 failed treatments, she was put on 6 rounds of Calyx, then Gemzar, which ended up attacking her bone marrow, for which she had a hard time. On August 2, 2010, her Canadian oncologist deemed her terminal and gave her approximately 2 months to live, but she and her husband were not prepared to accept that. Her husband began researching for other alternative cures and was impressed by the Issels Treatment. They also talked to another woman from Windsor, Ontario, who had experienced the treatment. In October 14, 2010 Sylvia came to the Issels Treatment Center in a very frail state, in a wheelchair, and unable to walk. In her own words: "In less than 3 weeks I was able to walk 6 blocks to the ocean from here...The doctors are very caring, they're very aggressive with their treatment, they're very hands-on. You're not a number." Her tumor marker Ca-125 was 141 when she started the Issels Treatment, and in less than 3 weeks it dropped down to 77.9. She feels stronger, more vibrant, and feel alive again. "I know I'm going to be healed. This is the place to be."
Views: 23247 Issels Immunotherapy
Michael J. Birrer, MD, PhD, director, Massaschusetts General Hospital Cancer Center, gynecologic medical oncology, discusses the 3 main treatment options available for women with platinum sensitive recurrent ovarian cancer, which he defines as having recurred greater than 6 months after their last platinum treatment. The current standard of care for platinum sensitive ovarian cancer includes 1 of 3 platinum doublets, each demonstrating a survival benefit in randomized trial. The first doublet contains a combination of carboplatin and paclitaxel (Taxol), this was investigated in the ICON4 trial, which demonstrated a median 13 month progression-free survival (PFS) and a 29 month overall survival (OS). The second doublet contains a combination of carboplatin and gemcitabine. This was demonstrated in the AGO-OVAR study with a median PFS of 8.6 months, which was the primary endpoint. The OS benefit was not deemed statistically significant. The third doublet is the most recently discovered; it contains a combination of carboplatin and Doxil. This study demonstrated a survival benefit that was similar to the carboplatin and Taxol combination. This new combination therapy is preferred because it is less toxic that the other doublets. Once the Doxil shortage is resolved it will most likely become the favored standard of care for many physicians.
Views: 738 OncLiveTV
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Dr Liu (Dana-Farber Cancer Institute, Boston, USA) presents her work regarding a new immunotherapy drug combo, cediranib plus olaparib, which has been shown to significantly increase progression-free survival in recurrent ovarian cancer.
Views: 129 ecancer
Angeles Alvarez Secord, MD, discusses the risk of recurrence of ovarian cancer with her patient, Michelle Berke. Dr Secord also explains how BRCA mutations play a role in the disease course and how she determines the best treatment option once cancer recurs. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Views: 26 curetoday
From http://www.beetmedicine.tv/2009/04/ovarian-cancer-is-not-silent-cancer-it-whispers.html: Ovarian cancer is rare and usually discovered at a late stage. The signs are symptoms are subtle and not dissimilar from other abdominal or pelvic complaints. The key is that they are persistent. Dr. Poynor describes this not as silent cancer but, a cancer which whispers. Workup includes a pelvic exam, a transvaginal ultrasound and possibly a CAT scan. CA 125 is a blood test which is useful in following women who have been treated for an ovarian cancer to monitor a recurrence. It is not sensitive enough to detect early ovarian cancer nor specific enough because it may be elevated in benign conditions. But, it can be used until better markers become available. Peter Pressman, MD Interviewee: Elizabeth Poynor, MD, PhD FACOG Gynecologic Oncologist
Views: 55252 BeetMedicineTV
Panelists Bradley J. Monk, MD; Katie Moore, MD; Robert L. Coleman, MD; Gottfried E. Konecny, MD; and Matthew A. Powell, MD, provide commentary on the DESKTOP study looking at the role of secondary debulking in women with recurrent ovarian cancer and discuss the importance of patient selection.
Views: 366 OncLiveTV
Department of Gynecology, The Second Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China Shi RX, MD Ding L, MD
Views: 65 Bin Tang
Robert L. Coleman, MD, summarizes the case of a 38-year-old woman diagnosed with metastatic platinum-resistant ovarian cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 174 Targeted Oncology
Bradley J. Monk, MD, FACS, FACOG; Thomas Herzog, MD; and Leslie M. Randall, MD, MAS, consider the goals of therapy in recurrent ovarian cancer and debate the use of secondary debulking as a treatment strategy based on data from the GOG-0213 phase III trial.
Views: 37 OncLiveTV
Panelists Bradley J. Monk, MD; Gottfried E. Konecny, MD; Katie Moore, MD; and Robert L. Coleman, MD, discuss the results of the SOLO-2 trial looking at olaparib maintenance in BRCA-mutated, platinum-sensitive relapsed ovarian cancer, and ongoing studies of olaparib-containing combinations.
Views: 714 OncLiveTV
Patient responded well to CA Care Therapy. One week on herbs, she felt good, no more abdominal pain and diarrhea. After 4 months, her CA 125 decreased from 409 to 228. Digital meridian imaging using AcuGraph 3 also showed overall improvement.
Views: 232 Chris Teo
A decade ago, women diagnosed with ovarian cancer had few options for treatment. Surgery, chemotherapy and radiation were standard practice. Those therapies are still in use today, but, thanks to research and new technologies, ovarian cancer patients have additional, and sometimes more effective, options for treatment.
Views: 1386 Mayo Clinic
Panelists Bradley J. Monk, MD; Matthew Powell, MD; Gottfried E. Konecny, MD; Robert L. Coleman, MD; and Katie Moore, MD, discuss the FDA approval of niraparib and the NOVA trial of niraparib maintenance therapy in recurrent platinum-sensitive ovarian cancer.
Views: 434 OncLiveTV
For Mary Sue David, It’s not just about getting through her treatment for stage IV ovarian cancer; it’s about living her life and thriving. Cancer survivor Mary Sue shares her journey with cancer, which has included #breastcancer and #ovariancancer. She talks about her initial fears from her diagnosis, her cancer treatment and how she stays upbeat, living one day at a time. Visit http://www.oacancer.com/living-with-ovarian-cancer-and-thriving/ to read more about Mary Sue's story. About Oncology Associates Oncology Associates provides personalized cancer care and treatment at two Omaha clinics, as well as at clinics in Blair and Norfolk, Nebraska. Please visit http://www.oacancer.com to learn more about their approach to treating cancer. The physicians of Oncology Associates include: * Irina E. Popa, MD #irinapopamd * Laxmi Narayana R. Buddharaju, MD ("Dr. Budd") #drbudd These videos are produced by Oncology Associates to help provide useful cancer information to cancer patients and survivors. Watch more cancer patient and #cancersurvivor videos here - http://www.oacancer.com/oncology-video-center/oncology-associates-patient-stories/
Views: 12887 Oncology Associates
We know that the topic of recurrence in cancer patients can be an overwhelming and scary issue for any ovarian cancer survivor. In this video, Dr. John Comerci leads a discussion on recurrence and openly answered many questions from our survivor audience -- hopefully yours will be one of them. We appreciate Dr. Comerci's contribution of his time and Magee Womens Hospital of UPMC for providing the resources to make this lecture series possible.
Views: 3571 NOCCNational
Silver Institute for Life Extension Medicine 7420 E Pinnacle Peak Rd. Suite #126 Scottsdale, AZ 85255 (480) 860-2030 http://deansilvermd.com Becky Zortman, R.N. Metastatic Ovarian cancer to abdomen and lungs Dr. Silver preformed a circulating cancer stem cell blood test to exactly determine which chemotherapy I should use and what natural substances worked on my cancer to kill it. He found out that I had many infections with poor mitochondria function and many free radicals . Dr. Silver started treating me with ozone and many other intravenous therapy. I gained my strength and energy back. Before the treatment I couldn't walk from the car to dr. Silver's office.The ozone has been a God's gift. The ozone has strengthened my whole body. It took about two weeks until I felt I was feeling better. My emotions were drained before seeing Dr. Silver and now I feel that I am able to fight my cancer. He also found I had a low thyroid and adrenal gland function and he repaired them. I can now walk 30 minutes a day . I can do my trampoline 10 minutes a day. I was around sick people at a funeral and I didn't get any sickness at all. I believe it was my ozone and vitamin C , vitamins, minerals and PolyMva intravenously. It was all powerful. I now know that my body is finally getting the nutrients it has so long badly needed. I want to thank Dr. Silver and the staff for treating me with such kindness and helping me. I am well today and I will get just better and better.
Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Views: 528 Targeted Oncology
Panelists Bradley J. Monk, MD; Matthew A. Powell, MD; Katie Moore, MD; Robert L. Coleman, MD; and Gottfried E. Konecny, MD, discuss the use of bevacizumab for recurrent advanced ovarian cancer, including the recent approval for platinum-sensitive disease.
Views: 603 OncLiveTV
Andreas Du Bois reports on results from two practice changing surgical studies conducted by European researchers in patients with ovarian cancer. First, the LION study gives evidence about lymphadenectomy outcome and the second study evaluates the use of the AGO score to select patients for surgery in recurrent ovarian cancer. Abstracts as referenced in the ASCO 2017 programme: 5500: LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. 5501: Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. Produced by the European Society for Medical Oncology http://www.esmo.oncologypro.org
Views: 1297 European Society for Medical Oncology
Many women experience disease recurrence after treatment of ovarian cancer, although a number of drugs have been developed that are effective in treating these recurrences and provide good long-term outcomes, explains Robert J. Morgan, MD, from City of Hope Comprehensive Cancer Center in this video from the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care for cancer patients. For more information on prostate cancer and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com.
Views: 1049 National Comprehensive Cancer Network® (NCCN®)
Panelists outline the management of metastatic and recurrent cervical cancer, including the use of bevacizumab.
Views: 883 OncLiveTV
Peritoneal & lymph node recurrence 7 years after T3bN0M0 ovarian cancer treatment (hysterectomy, omentectomy & 6 courses of chemotherapy, 2008). Laparoscopic biopsy of pelvic mass, paracaval & external iliac lymph nodes.
Views: 2013 Dr. Sergey Baydo
Cancer Research Institute postdoctoral fellow Juan Cubillos-Ruiz, Ph.D., of Weill Cornell Medical College, discusses the research he is pursuing to improve survival for patients with metastatic ovarian cancer. Dr. Cubillos-Ruiz studies a cellular process called the endoplasmic reticulum (ER) stress response. He has shown that targeting the ER stress response in immune cells of the tumor environment can halt tumor progression. This research is helping to improve cancer immunotherapies and gives hope to the nearly 22,000 women in the U.S. who are diagnosed with ovarian cancer each year. To learn more about how cancer immunotherapy is changing lives, visit www.cancerresearch.org.
Views: 874 Cancer Research Institute
How to treat Recurrent Cancer Current treatment of recurrent cancer is not optimal since medicine ignores that organism resists the tumor. Host resistance may be weak yet it is significant. Obviously if host resistance is high patient requires less drugs and vice versa. Here is an example of therapy which considers host resistance. A woman leaving mammography with a localized breast tumor is treated and tumor is removed. In most women treatment will leave behind tumor remnants too small to be detected. They will grow and later on present as recurrent tumors. The question is how to treat them optimally? I maintain that breast cancer is driven by a virus to which it responds with a tumor. During an aggressive virus infection tumor grows faster and vice versa. I regard tumor as biomarker of two processes: 1. Severity of virus infection 2. Host resistance. Once cancer recurs it is essentially incurable, and the only therapeutic objective is dormancy induction. Cancer dormancy has two manifestations: 1. Tumor stops growing or grows extremely slowly. 2. Tumor is invisible Dormancy induction requires small drug doses. You start with a small dose. Rise it gradually until dormancy is achieved. The initial small dose depends on the time of tumor recurrence. The later tumor recurs the smaller dose is needed
Views: 1115 Gershom Zajicek M.D,
Adam M. Brufsky, MD, PhD, FACP; Komal Jhaveri, MD, FACP; Hope S. Rugo, MD; Francisco Esteva, MD, PhD; and Lee Schwartzberg, MD, FACP, discuss the 8-year results of the SOFT and TEXT trials looking at ovarian suppression with endocrine therapy in premenopausal women with hormone receptor–positive breast cancer.
Views: 190 OncLiveTV